Seattle Genetics on Friday received its third FDA approval, a regulatory nod for a breast cancer drug for patients with an especially aggressive form of the disease, four months ahead of schedule.

The Bothell, WA-based biotech earned the earlier-than-expected decision for its oral drug tucatinib (Tukysa), when taken in combination with the chemotherapies trastuzumab and capecitabine. The approval covers patients with a subtype of breast cancer that overproduces human epidermal growth factor receptor 2, or HER2, that can’t be surgically removed or has spread beyond its primary site.

Patients approved to receive the Seattle Genetics (NASDAQ: SGEN) treatment, who must… Read more »

UNDERWRITERS AND PARTNERS